These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22002809)

  • 1. Model-based determination of abatacept exposure in support of the recommended dose for Japanese rheumatoid arthritis patients.
    Hasegawa M; Imai Y; Hiraoka M; Ito K; Roy A
    J Pharmacokinet Pharmacodyn; 2011 Dec; 38(6):803-32. PubMed ID: 22002809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis.
    Roy A; Mould DR; Wang XF; Tay L; Raymond R; Pfister M
    J Clin Pharmacol; 2007 Nov; 47(11):1408-20. PubMed ID: 17962428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Pharmacokinetics and Exposure-Response Relationship of Intravenous and Subcutaneous Abatacept in Patients With Rheumatoid Arthritis.
    Li X; Roy A; Murthy B
    J Clin Pharmacol; 2019 Feb; 59(2):245-257. PubMed ID: 30229926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Model-Based Selection and Recommendation for Subcutaneous Abatacept Dose in Patients With Polyarticular Juvenile Idiopathic Arthritis.
    Gandhi Y; Passarell JA; Roy A; Murthy B
    J Clin Pharmacol; 2021 May; 61(5):688-699. PubMed ID: 33284480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study.
    Iwahashi M; Inoue H; Matsubara T; Tanaka T; Amano K; Kanamono T; Nakano T; Uchimura S; Izumihara T; Yamazaki A; Karyekar CS; Takeuchi T
    Mod Rheumatol; 2014 Nov; 24(6):885-91. PubMed ID: 24708204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
    Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate.
    Takeuchi T; Matsubara T; Nitobe T; Suematsu E; Ohta S; Honjo S; Abe T; Yamamoto A; Miyasaka N;
    Mod Rheumatol; 2013 Mar; 23(2):226-35. PubMed ID: 22684431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.
    Genovese MC; Covarrubias A; Leon G; Mysler E; Keiserman M; Valente R; Nash P; Simon-Campos JA; Porawska W; Box J; Legerton C; Nasonov E; Durez P; Aranda R; Pappu R; Delaet I; Teng J; Alten R
    Arthritis Rheum; 2011 Oct; 63(10):2854-64. PubMed ID: 21618201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis.
    Teng GG; Turkiewicz AM; Moreland LW
    Expert Opin Biol Ther; 2005 Sep; 5(9):1245-54. PubMed ID: 16120053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of abatacept in the management of rheumatoid arthritis.
    Nogid A; Pham DQ
    Clin Ther; 2006 Nov; 28(11):1764-78. PubMed ID: 17212998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study.
    Weinblatt ME; Schiff M; Valente R; van der Heijde D; Citera G; Zhao C; Maldonado M; Fleischmann R
    Arthritis Rheum; 2013 Jan; 65(1):28-38. PubMed ID: 23169319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs.
    Takeuchi T; Matsubara T; Urata Y; Suematsu E; Ohta S; Honjo S; Abe T; Yamamoto A; Miyasaka N;
    Mod Rheumatol; 2014 Sep; 24(5):744-53. PubMed ID: 24754273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exposure-response modeling of peficitinib efficacy in patients with rheumatoid arthritis.
    Toyoshima J; Kaibara A; Shibata M; Kaneko Y; Izutsu H; Nishimura T
    Pharmacol Res Perspect; 2021 May; 9(3):e00744. PubMed ID: 33929089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetic and Exposure-Response Model Simulations: Predicted Exposure and Efficacy for Maintenance Doses of Intravenous Golimumab Every 6 or 8 Weeks in Patients With Moderately to Severely Active Rheumatoid Arthritis.
    Lee JB; Broadwell A; Fan Y; Hu C; Adedokun OJ; Chakravarty SD; Zhou H; Xu Z; Leu JH
    Clin Ther; 2022 Mar; 44(3):457-464.e2. PubMed ID: 35183373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 7-year extended study.
    Westhovens R; Kremer JM; Emery P; Russell AS; Alten R; Barré E; Dougados M
    Clin Exp Rheumatol; 2014; 32(4):553-62. PubMed ID: 25005467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom.
    Guyot P; Taylor PC; Christensen R; Pericleous L; Drost P; Eijgelshoven I; Bergman G; Lebmeier M
    J Rheumatol; 2012 Jun; 39(6):1198-206. PubMed ID: 22505698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability and efficacy of abatacept in Japanese patients with rheumatoid arthritis: a phase I study.
    Matsubara T; Yamana S; Tohma S; Takeuchi T; Kondo H; Kohsaka H; Ozaki S; Hashimoto H; Miyasaka N; Yamamoto A; Hiraoka M; Abe T
    Mod Rheumatol; 2013 Jul; 23(4):634-45. PubMed ID: 22833376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.
    Kremer JM; Dougados M; Emery P; Durez P; Sibilia J; Shergy W; Steinfeld S; Tindall E; Becker JC; Li T; Nuamah IF; Aranda R; Moreland LW
    Arthritis Rheum; 2005 Aug; 52(8):2263-71. PubMed ID: 16052582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.
    Kremer JM; Genant HK; Moreland LW; Russell AS; Emery P; Abud-Mendoza C; Szechinski J; Li T; Ge Z; Becker JC; Westhovens R
    Ann Intern Med; 2006 Jun; 144(12):865-76. PubMed ID: 16785475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profile of abatacept in rheumatoid arthritis: a review.
    Khraishi M; Russell A; Olszynski WP
    Clin Ther; 2010 Oct; 32(11):1855-70. PubMed ID: 21095481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.